Sector: Healthcare / MedTech
Platform: Republic Europe (Seedrs)
Stage: Growth
Minimum investment: £30
What They Do
Occuity develops handheld, non-contact optical devices that screen and monitor chronic diseases by scanning the eye instead of using invasive tests.
Why It Might Be the Next Big Thing
Screening for conditions like glaucoma, diabetes and myopia remains slow, invasive and difficult to scale. Occuity aims to move early detection into primary care, optometry networks and retail health environments using non-invasive eye scanning.
Who’s Backing Them
A large base of Republic Europe (Seedrs) investors across multiple rounds.
Snapshot
CE-marked PM1 pachymeter selling through 19 distributors
15+ patents across its optical diagnostics platform
Roadmap includes devices for glaucoma, myopia, diabetes and Alzheimer’s screening
My Take
A strong combination of IP, regulatory progress and a multi-product pipeline. Occuity is positioned more like a diagnostics platform than a one-device company.